Shifting our thinking about uncommon disease trials: The case of methotrexate in scleroderma

Journal of Rheumatology

Volumn 36, Issue 2, 2009, Pages 323-329

  Johnson, Sindhu R ^a,b,e   Feldman, Brian M ^a,b   Pope, Janet E ^a,c   Tomlinson, George A ^b,d  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Bayesian analysis; Methotrexate; Rare disease trials; Scleroderma

Indexed keywords

METHOTREXATE; PLACEBO; ANTIRHEUMATIC AGENT;

ADULT; ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG WITHDRAWAL; HUMAN; MOUTH ULCER; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROBABILITY; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; METHODOLOGY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RARE DISEASE; REPRODUCIBILITY; SKIN DISEASE; STANDARD; STATISTICAL ANALYSIS; STATISTICS;

ADULT; ANTIRHEUMATIC AGENTS; BAYES THEOREM; CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; DOUBLE-BLIND METHOD; HUMANS; METHOTREXATE; OUTCOME ASSESSMENT (HEALTH CARE); PLACEBOS; RARE DISEASES; REPRODUCIBILITY OF RESULTS; SCLERODERMA, SYSTEMIC; SKIN DISEASES; TREATMENT OUTCOME;

EID: 64849103964     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.071169     Document Type: Article

References (36)

1. Cox SR, Walker JG, Coleman M, et al. Isolated pulmonary hypertension in scleroderma. Intern Med J 2005;35:28-33. (Pubitemid 40254764)
2. Fisher RA. Statistical methods and statistical inference. Edinburgh: Oliver and Boyd; 1956.
3. Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ 1995;311:485.
4. Alderson P, Chalmers I. Survey of claims of no effect in abstracts of Cochrane reviews. BMJ 2003;326:475. (Pubitemid 36269628)
5. Bedard PL, Krzyzanowska MK, Pintilie M, Tannock IF. Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings. J Clin Oncol 2007;25:3482-3487 (Pubitemid 47310887)
6. Goodman SN. Toward evidence-based medical statistics. 1: The P value fallacy. Ann Intern Med 1999;130:995-1004.
7. Yusuf S, Collins R, Peto R, et al. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J 1985;6:556-585 (Pubitemid 15046383)
8. Wijeysundera DN, Austin PC, Hux JE, Beattie WS, Laupacis A. Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials. J Clin Epidemiol 2008 Oct 21. [E pub ahead of print]
9. Burton PR. Helping doctors to draw appropriate inferences from the analysis of medical studies. Stat Med 1994;13:1699-1713 (Pubitemid 24284853)
10. Salsburg D. The religion of statistics as practiced in medical journals. Am Stat 1985;39:220-223
11. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-799 (Pubitemid 28225778)
12. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003;48:2246-2255 (Pubitemid 36959206)
13. Johnson SR, Gladman DD, Schentag CT, Lee P. Quality of life and functional status in systemic sclerosis compared to other rheumatic diseases. J Rheumatol 2006;33:1117-1122 (Pubitemid 43825462)
14. Bode BY, Yocum DE, Mann CC, Ko M, Boyer J. Methotrexate (MTX) in scleroderma: experience in ten patients [abstract]. Arthritis Rheum 1990;33 Suppl:S66.
15. van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996;35:364-372 (Pubitemid 26136688)
16. Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44:1351-1358 (Pubitemid 32537533)
17. Pope JE, Ouimet JM, Krizova A. Scleroderma treatment differs between experts and general rheumatologists. Arthritis Rheum 2006;55:138-145 (Pubitemid 43235139)
18. Burton PR, Gurrin LC, Campbell MJ. Clinical significance not statistical significance: a simple Bayesian alternative to p values. J Epidemiol Community Health 1998;52:318-323 (Pubitemid 28230616)
19. Spiegelhalter DJ, Abrams KR, Myles JP. An overview of the Bayesian approach. In: Spiegelhalter DJ, Abrams KR, Myles JP, editors. Bayesian approaches to clinical trials and health care evaluation. Chichester: John Wiley & Sons; 2004:49-137.
20. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-590
21. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-205 (Pubitemid 18073738)
22. Furst DE, Clements PJ, Hillis S, et al. Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study. Arthritis Rheum 1989;32:584-593
23. Kahaleh MB, Sultany GL, Smith EA, Huffstutter JE, Loadholt CB, LeRoy EC. A modified scleroderma skin scoring method. Clin Exp Rheumatol 1986;4:367-369 (Pubitemid 17223177)
24. Sung L, Hayden J, Greenberg ML, Koren G, Feldman BM, Tomlinson GA. Seven items were identified for inclusion when reporting a Bayesian analysis of a clinical study. J Clin Epidemiol 2005;58:261-268 (Pubitemid 40249468)
25. Martin AD, Quinn KM. MCMCpack: Markov chain Monte Carlo (MCMC) package. R package version 0.8-1 2007. [Internet. Accessed Sept 30 2008.] Available from: http://mcmcpack.wustl.edu
26. Rossi P, McCulloch R. bayesm: Bayesian inference for marketing/micro- econometrics. R package version 2.0-9 2007. [Internet. Accessed Sept 30 2008.] Available from: http://faculty.chicagogsb.edu/peter.rossi/research/bsm.html
27. Sturtz S, Ligges U, Gelman A. R2WinBUGS: A package for running WinBUGS from R. J Statistical Software 2005;12:1-16. (Pubitemid 40218003)
28. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005;118:2-10. (Pubitemid 40082450)
29. Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 2006;367:1683-1691
30. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310:452-454
31. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988;318:1728-1733 (Pubitemid 18156674)
32. Chatellier G, Zapletal E, Lemaitre D, Menard J, Degoulet P. The number needed to treat: a clinically useful nomogram in its proper context. BMJ 1996;312:426-429 (Pubitemid 26055360)
33. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 1999;319:1492-1495
34. Moye LA. Bayesians in clinical trials. Asleep at the switch. Stat Med 2008;27:469-82; discussion 483-489
35. Knipschild P. Changing belief in iridology after an empirical study. BMJ 1989;299:491-492 (Pubitemid 19204925)
36. Rovers MM, van der Wilt GJ, van der Bij S, Straatman H, Ingels K, Zielhuis GA. Bayes' theorem: a negative example of a RCT on grommets in children with glue ear. Eur J Epidemiol 2005;20:23-28 (Pubitemid 40202680)